Clinical Policy: Bariatric Surgery
Reference Number: WA.UM.30
Effective Date: 11/14
Last Review Date: 3/18

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
There are two categories of bariatric surgery: restrictive procedures and malabsorptive procedures. Gastric restrictive procedures include procedures where a small pouch is created in the stomach to restrict the amount of food that can be eaten, resulting in weight loss. The laparoscopic adjustable gastric banding (LAGB) and laparoscopic sleeve gastrectomy (LSG) are examples of restrictive procedures. Malabsorptive procedures bypass portions of the stomach and intestines causing incomplete digestion and absorption of food. Duodenal switch is an example of a malabsorptive procedure. Roux-en-y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD-DS), and biliopancreatic diversion with gastric reduction duodenal switch (BPD-GRDS) are examples of restrictive and malabsorptive procedures.

LAGB devices are currently not FDA approved for adolescents less than 18 years, but an industry-sponsored prospective study is in progress, and numerous retrospective studies of adolescents have been published with favorable results.

Policy/Criteria
Coordinated Care authorizes bariatric surgery and bariatric surgery related services in three stages:

1. Initial assessment of member (no authorization required)
2. Evaluation for bariatric surgery and successful completion of a weight loss regimen
3. Bariatric surgery

It is the policy of Coordinated Care that the bariatric surgery procedures LAGB, LSG, and laparoscopic RYGB for adults and laparoscopic BPD-DS/BPD-GRDS for adults are medically necessary when meeting the following criteria.

A. **Stage 2 Evaluation for bariatric surgery**– if member meets the following criteria
   1. Age 21-59 years of age (see below for over age 59)
      a. BMI ≥ 35 kg/m² and at least one of the following comorbidities:
         - Diabetes Mellitus
         - Pseudotumor cerebri
         - Other rare conditions where there is evidence that bariatric surgery is medically necessary and benefits outweigh the risks of surgical mortality
         - Degenerative joint disease of a major weight bearing joint(s) (the client must be a candidate for joint replacement surgery if weight loss is achieved)
2. Age 18-20 (only laparoscopic adjustable gastric banding, LAGB)
   b. $\geq 35 \text{ kg/m}^2$ and at least one of the following comorbidities:
      1. Diabetes Mellitus
      2. Pseudotumor cerebri
      3. Other rare conditions where there is evidence that bariatric surgery is medically necessary and benefits outweigh the risks of surgical mortality
      4. Degenerative joint disease of a major weight bearing joint(s) (the client must be a candidate for joint replacement surgery if weight loss is achieved)

Members over 59 years of age can be considered on a case by case basis if the other criteria under 1 above (BMI and appropriate comorbidities) are met. Risks are higher and outcomes less good in this age group, so the member’s overall health status and appropriateness must be carefully considered. All requests for members over age 59 require an automatic secondary review.

B. Stage 3 Bariatric surgery – if member meets the criteria in sections II and III. Decision regarding procedure selection is up to client and surgeon, with the exception of individuals 18-20 who are eligible for LAGB only when criteria in section II and III are met.

1. **Location of services**- Bariatric surgery must be performed in a hospital with a bariatric surgery program, and the hospital must be located in the state of Washington or approved border cities. The program must be a Center of Excellence or have accreditation by

2. **Continued obesity despite compliance with supervised dietary/nutritional therapy** and behavior modification program for at least 6 months with all of the following documented; unless waiting for attempted weight loss could result in worsening of a health condition:
   1. Initial comprehensive diet history to include assessment of current pattern of nutrition and exercise and steps to modify problem eating behaviors, and
   2. Prescribed exercise program, and
   3. The provider must document the member’s compliance in keeping scheduled appointments and the client’s progress toward weight loss by serial weight recordings.
   4. For diabetic members the provider must document the efforts in diabetic control or stabilization.
   5. Twice monthly counseling by a registered dietician who must document the member’s compliance (or noncompliance) in keeping scheduled appointments, and the client’s weight loss progress
   6. Include monthly visits to a licensed medical provider.
7. Within 180 days of the Stage 2 authorization, lose at least 5 percent of initial body weight (initial body weight will be determined at the first evaluation appointment) and maintain weight loss.

8. If the member does not meet this weight loss requirement within 180 days, the member or member’s provider must request Stage 2 authorization again. An extension of the authorization can be requested prior to the end of the authorization.

3. **Preoperative evaluation and medical evaluation** requirements within 6 months of the scheduled surgery includes all of the following:

   I. Cardiac evaluation includes an electrocardiogram and one of the following categories (1 or 2):
      1. **LOW CARDIAC RISK** candidates need cardiac assessment and it is the discretion of the PCP or cardiologist if additional cardiac testing is needed. If additional testing is needed, it should be conducted by a cardiologist.
         - Low risk candidates include those with all of the following:
           - 1 or less comorbidities
           - No known ischemic heart disease
           - No known structural heart disease or murmurs
      2. **HIGH CARDIAC RISK** candidates need consultation/evaluation from a cardiologist. High risk candidates include those with any of the following:
         - Diabetes type I for any length or type II for > 5 Years
         - Uncontrolled HTN
         - Structural heart disease
         - Ischemic heart disease or have had a cardiac event
         - CHF
         - Arrhythmia or history of arrhythmia
         - Age > 40 years with ≥ 2 or more comorbidities

   II. Glycemic control should be optimized as evidenced by one of the following:
      1. HbA1c 6.5% - 7.0%
      2. Fasting blood glucose level of ≤ 110 mg/dL
      3. 2-hour postprandial blood glucose concentration of ≤ 140 mg/dL
      4. HbA1c of 7% - 8% in candidates with advanced microvascular or macrovascular complications, extensive co-morbid conditions, or long-standing diabetes in which the general goal has been difficult to attain despite intensive efforts.
      5. Adherent to lifestyle modification and medication management as ordered by treating provider

   III. Pulmonary Evaluation:
      1. Chest x-ray
      2. Screening for obstructive sleep apnea
      3. Pulmonary function testing and ABG analysis for candidates with intrinsic lung disease or disordered sleep patterns

   IV. Polysomnography for evaluation of obstructive sleep apnea in members who meet at least one of the following criteria for PSG:
1. Recurrent witnessed apnea during sleep > 10 seconds in duration;
2. Excessive or inappropriate daytime sleepiness such as falling asleep while
driving or eating;
3. Sleepiness that interferes with daily activities not explained by other
conditions, such as poor sleep hygiene, medication, drugs, alcohol, psychiatric
or psychological disorders;
4. Having an Epworth Sleepiness Scale score greater than 10;
5. Persistent or frequent disruptive snoring, choking or gasping episodes
associated with awakenings;

V. Specialist may be consulted for interpretation of any abnormal findings
1. Physical maturity (members <18 years of age) - completed 95% of predicted
adult stature based on bone age or reaching Tanner stage IV
2. Bone age is determined by an x-ray of the wrist and hand that gives an
estimate of how mature a child’s bones are in years. Using this age and other
factors, the child’s predicted adult height is calculated. The percent of adult
height achieved is simply the child’s current height divided by the predicted
adult height.

VI. Nutritional evaluation, including micronutrient measurements and treatment of
insufficiencies/deficiencies prior to surgery

VII. Ongoing nutritional counseling
1. Beyond initial 6 months of counseling, monthly nutritional counseling will
continue until the date of the surgery.
2. Must provide documentation that counseling has been conducted regarding
the success of weight loss surgery dependent on post-op diet modification

VIII. Exercise commitment
1. Exercise program must be documented to include daily exercise for the entire
pre-operative period from the time a member enters into nutritional counseling
to the time of surgery.
2. Exercise logs must demonstrate an 80% compliance rate to be considered for
approval for surgery.

IX. Age appropriate psychiatry/psychology consultation, must be performed by a
psychiatrist, psychiatric certified ARNP, or licensed social worker with a
minimum of two years post-masters work in mental health:
1. An in-person psychological evaluation to assess for major mental health
disorders which would contradict surgery and determine ability to comply
with post-operative care and guidelines; and
2. If history is positive for alcohol or drug abuse, meets both of the following:
   a. Must provide documentation of alcohol and drug abstinence for ≥ 1 year
      prior to surgery;
   b. Negative urine drug screen within 3 months of request;
3. If applicable, document that the client has been successfully treated for
   psychiatric illness and has been stabilized for at least six months

X. Members at risk for primary hypothyroidism are screened with a TSH level and
treated if found to be hypothyroid.

XI. A fasting lipid panel must be obtained and treatment initiated for dyslipidemia.

XII. Screening for Helicobacter Pylori in high-prevalence areas
XIII. Prophylactic treatment for gouty attacks in patients with a history of gout

XIV. If tobacco user, must stop use > 6 weeks prior to surgery

XV. Member is not pregnant

C. Repeat/Revision Surgeries

A. Repeat bariatric surgery or bariatric surgery revision is considered medically necessary for one of the following:
   1. To correct complications from a previous bariatric surgery, such as obstruction and/or strictures, or
   2. Conversion from LAGB to a RYGB or BPD-DS; or revision of a primary procedure that has failed due to dilation of the gastric pouch when all of the following criteria are met:
      a. All criteria listed above for the initial bariatric procedure must be met again.
      b. Previous surgery for morbid obesity was at least 3 years prior to repeat procedure.
      c. Weight loss from the initial procedure was less than 50% of the member's excess body weight at the time of the initial procedure.
      d. Documented compliance with previously prescribed postoperative nutrition and exercise program.

D. Reversal
   1. Reversal of a bariatric surgery without revision is medically necessary if the member is experiencing adverse outcomes from a bariatric surgery procedure.

E. Contraindications for surgical weight loss procedures include:
   o Medically correctable cause of obesity
   o An ongoing substance abuse problem within the preceding year
   o Patients with untreated major depression or psychosis
   o A medical, psychiatric, psychosocial, or cognitive condition that prevents adherence to post-operative dietary and medication regimens or impairs decisional capacity
   o Current or planned pregnancy within 12 to 18 months of the procedure
   o Severe cardiac disease with prohibitive anesthetic risks
   o Severe uncorrectable coagulopathy
   o Inability on the part of the patient or parent (if adolescent) to comprehend the risks and benefits of the surgical procedure.

F. It is the policy of CCW that the following bariatric surgery procedures are considered investigational, because the medical literature indicates that studies have been inadequate to determine their efficacy and long-term outcomes:
   o Distal gastric bypass (very long limb gastric bypass);
   o Loop Gastric Bypass ("Mini-Gastric Bypass");
   o Laparoscopic re-sleeve gastrectomy (LRSG) performed after the resulting gastric pouch is primarily too large or dilates after the original LSG;
   o Fobi pouch;
   o Laparoscopic greater curvature plication (Gastric Imbrication);
   o LAP-BAND when BMI is 30 to 35 with or without comorbid conditions;
   o Endoscopic Suture Revisions post bariatric surgery.
G. It is the policy of CCW that the following bariatric surgery procedures are considered **not medically necessary**, due to potential complications and a lack of positive outcomes:

- Biliopancreatic diversion (BPD) procedure (also known as the Scopinaro procedure);
- Jejunoileal bypass (jejuno-colic bypass);
- Vertical Banded Gastroplasty (VBG);
- Gastric balloon;
- Gastric pacing;
- Gastric wrapping.

**Background**
There is sufficient evidence in peer-reviewed medical literature to support the use of the above mentioned bariatric surgeries for the clinically obese individual. Persons with clinically severe obesity are at risk for increased mortality and multiple co-morbidities. These co-morbidities include hypertension, hypertrophic cardiomyopathy, hyperlipidemia, diabetes, cholelithiasis, obstructive sleep apnea, hypoventilation, degenerative arthritis and psychosocial impairments.

The majority of severely obese patients losing weight through non-operative methods alone regain all the weight lost over the next five years. Surgical treatment is the only proven method of achieving long term weight control for the morbidly obese. Eating behaviors after surgery improve dramatically due to the restricted size of the stomach allowing only small amounts of food to be taken in at a time.

The success of the bariatric surgery does rely on the motivation and dedication to the program of the patient. The patient must be able to participate in the treatment and long-term follow up required after surgery. Studies have shown that about 10% of patients may have unsatisfactory weight loss or regain much of the weight they have lost. This may occur due to frequent snacking on high-calorie foods or lack of exercise. Technical problems that may occur include a stretched pouch due to overeating following surgery. Ensuring patients are motivated to lose weight can help prevent some of these issues.

Maximum weight loss usually occurs between 18 and 24 months postoperatively. The average weight loss at five years ranges from 48 to 74% after gastric bypass and 50 to 60% following gastric banding. Several studies have follow-up from 5-15 years with these patients maintaining weight loss of 50-60% of excess weight.

The Lap Band is a small bracelet-like band placed around the top of the stomach to produce a small pouch about the size of a thumb. The size of the outlet is controlled by a circular balloon inside the band that can be inflated and deflated with saline solution through an access port placed under the skin. The more inflated the balloon, the narrower the opening and slower passage of food to the rest of the stomach.

Roux-en-Y gastric bypass (RYGB) creates a small stomach pouch, bypassing most of the stomach, duodenum, and upper intestine. Weight loss occurs through restriction of food intake and by decreasing the absorption of food by re-routing food directly from the pouch into the small intestine.
Biliopancreatic diversion with duodenal switch (BPD-DS) is a complex operation that includes 1) removing a large portion of the stomach to promote smaller meal sizes, 2) re-routing of food away from much of the small intestine to partially prevent absorption of food, and 3) re-routing of bile and other digestive juices which impair digestion. The operation bypasses most of the duodenum, but leaves a small portion for food and the absorption of some vitamins and minerals. BPD-DS produces significant weight loss, but has a greater risk of long-term complications due to decreased absorption of food, vitamins, and minerals.

There are both early and later complications associated with these operations. Early complications can include bleeding, infections, leaks from suture sites and blood clots. Strictures, hernias, and malnutrition, especially when not taking prescribed vitamins and minerals, are all late complications that can occur in addition to the above mentioned stretched pouch or separated stitches. A repeat surgery is at times required to repair some of these complications.

**Bariatric Surgery in Adolescents**

Weight loss surgery has been performed in small groups of adolescents since the 1970s. Recent data has shown a significant increase in the rate since 2000. It is likely that we will continue to see a rise in the rate of adolescents undergoing weight loss surgery with the current pediatric obesity epidemic. Children and adolescents who are severely obese are at risk for the same mortality and co-morbidities as adults. These co-morbidities include hypertension, hypertrophic cardiomyopathy, hyperlipidemia, diabetes, cholelithiasis, obstructive sleep apnea, depression and impaired quality of life. In addition, children in the BMI category $\geq 35$ kg/m$^2$ will almost always remain obese and 65% will have a BMI $\geq 40$ as an adult.

Changes in diet and physical activity must be attempted prior to weight loss surgery in adolescents. A multi-disciplinary, family-based approach should be undertaken to support a staged weight loss plan. However, studies suggest that dietary and behavioral interventions rarely result in significant and sustained weight loss in adolescents. This same multi-disciplinary and family approach must be taken when evaluating and planning for bariatric surgery in an adolescent.

The multi-disciplinary team should include an experienced bariatric surgeon, pediatric obesity specialist, nurse, dietician, and pediatric psychologist or psychiatrist. Additional sub-specialists must be readily available for evaluation of co-morbidities. The success of the bariatric surgery does rely on the motivation and dedication to the program of the patient and their family. The patient and family must be willing and able to participate in the treatment and long-term follow up required after surgery. The adolescent must show evidence of mature decision-making with appropriate understanding of the risks and benefits of surgery.

Current existing retrospective data on adolescent weight loss surgery demonstrate that both bypass and banding lead to clinically significant and durable decrease in weight loss and BMI. Obesity-related diseases also improve or resolve after surgically induced weight loss in adolescents. There have not been enough studies to indicate what the long-term weight loss
sustainability is in adolescents. Specific predictors of weight regain after bariatric surgery are still unknown.

**Investigational Procedures**

Long-limb or Distal Gastric Bypass for Superobesity: An RCT has recently been completed by Svanevik et al., but only perioperative outcomes have been reported thus far. Svanevik et al. found that in superobese patients with BMI between 50 and 60 kg/m(2), distal gastric bypass was associated with longer operating time and more severe complications resulting in reoperation than proximal gastric bypass. There is increased risk of adverse nutritional outcomes with longer limb gastric bypass. At this time the long-limb or distal gastric bypass for superobesity is considered investigational, until more long-term studies can be done which reflect better outcomes than existing procedures.

Loop Gastric Bypass (Mini Gastric Bypass): The mini gastric bypass has not been universally accepted due to higher rates of alkaline bile reflux and limited long-term research. More long-term research is needed to solidify mini gastric bypass surgery’s position as a viable bariatric surgery option.

Re-Sleeve Gastrectomy for Failed Laparoscopic Sleeve Gastrectomy: Iannelli et al. (2012) noted that laparoscopic sleeve gastrectomy (LSG) was rapidly accepted as a valuable bariatric procedure before its effectiveness on weight loss in the long-term is clearly demonstrated. The authors report a feasibility study including 13 patients undergoing a redo LSG for either progressive weight regain after initial weight loss of insufficient weight loss. AlSabah et al. describe 24 patients who underwent re-sleeve laparoscopic gastrectomy after an initial LSG. Compared to 12 patients that initially had LSG, which was converted to LRYGB, results were similar, with no significant differences in percent of excess weight loss at one year. They conclude that larger and longer follow-up studies are needed to verify results.

Fobi Pouch or Silastic® Ring: The Fobi Pouch bariatric operation for obesity is a combination of stomach reduction and gastric bypass. The Silastic ring is placed around the vertically constructed gastric pouch above the anastomosis between the pouch and the intestinal Roux limb. Possible long term nutritional deficiencies involve fat soluble vitamin deficiencies of Calcium, Iron, B12, and Folic Acid. Patients are placed on nutritional supplements for the rest of their lives, and yearly monitoring is needed. The Fobi Pouch gastric bypass takes about double the time that a vertical banded gastroplasty operation takes. There is limited research on the outcomes of the fobi pouch versus other bariatric surgery procedures.

Gastric Imbrication: Fried et al. (2011) completed a 3-year RCT on the safety and efficacy of laparoscopic adjustable gastric banding with and without imbrication sutures. The results of the RCT have demonstrated that SAGB combined with a conservative approach to band adjustments and limited retrogastric dissection is effective and safe with and without imbrication sutures. Not using imbrication sutures results in significant benefits in operative speed with comparable clinical weight loss and intermediate term safety. Sharma et al. conducted a randomized, double blinded trial comparing LSG and laparoscopic gastric imbrication (LGI). They found no differences in weight, age, or BMI preoperatively at 6 months or 3 years between the two groups.
Endoscopic Suture Revisions Post Bariatric Surgery: To enhance weight loss, endoscopic procedures to promote restriction of the pouch or stoma include sclerotherapy of the site using 6 to 30 mL of sodium morrhuate injected circumferentially; tissue plication systems to reduce the size of the gastrojejunostomy and the gastric pouch; revisional surgery using a tissue plication device known as StomaPhyX to reduce the pouch size; and application of the endoclip to reduce the size of the gastrojejunal anastomosis. As noted in the Scientific Rationale Update for November 2012, there is a lack of long-term outcomes for endoscopic suture revisions post RYGB.

Not Medically Necessary Procedures

Biliopancreatic Diversion (BPD) Procedure (Scopinaro procedure): The biliopancreatic diversion (BPD) is a malabsorptive procedure that was introduced as a solution to the high rates of liver failure resulting from bowel exclusion in the jejunoileal bypass. The procedure consists of a partial gastrectomy and gastroileostomy with a long segment of Roux limb and a short common channel, resulting in fat and starch malabsorption. BPD also has a restrictive component. The BPD/DS procedure differs from the BPD in the portion of the stomach that is removed, as well as preservation of the pylorus. This allows more forward flow of the contents of the biliopancreatic limb and avoids the complications of stasis that plagued the jejunoileal bypass (JIB). It is associated with fewer complications than BPD alone. BPD/DS is a complex procedure that is only performed at a few centers in the U.S.

Jejunoileal Bypass or Jejunoileal Intestinal Bypass (JIB): The jejunoileal bypass (also called the intestinal bypass) is performed by dividing the jejunum close to the ligament of Treitz and connecting it a short distance proximal to the ileocecal valve, thereby diverting a long segment of small bowel, resulting in malabsorption. This procedure is no longer performed due to the high complication rate and frequent need for revisional surgery. Per the American Society for Metabolic & Bariatric Surgery, the JIB is no longer a recommended bariatric surgical procedure. The lessons learned from the JIB include the crucial importance of long-term follow-up and the dangers of a permanent, severe and global malabsorption.

Vertical Banded Gastroplasty (VBG): VBG has fallen out of favor as a restrictive procedure for severe obesity, due largely to the advantages of adjustable gastric banding. VBG requires division of the stomach or intestinal resection, while LAGB does not. In addition, the staples used in VBG may break down and cause weight regain, and VBG requires the use of prosthetic mesh that may increase the incidence of stomach stenosis. Thus, CMS says in their National Coverage Determination for Bariatric Treatment for Morbid Obesity that “VBG procedures are essentially no longer performed.”

Gastric Balloon: Previous endoscopic technologies used to treat obesity endoscopically, such as the gastric balloon, had limited exposure in the U.S. and were removed from the market because of associated complications, such as balloon deflation with migration and resultant small intestinal obstruction.

Gastric Pacing: A number of procedures have been investigated for weight loss surgery but have not been totally accepted by the surgical community. Gastric pacing has been performed in several trials but has not been shown to have any long-term effect and has been abandoned.
Gastric Wrapping: A gastric wrap is minimally invasive surgery and involves folding the stomach in on itself and then the edges are stitched to turn the stomach into a narrow tube therefore restricting the amount of food that can be consumed. As this surgery is very new and not widely offered. There is a paucity of peer-reviewed scientific literature on this procedure.

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2015, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>43644</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)</td>
</tr>
<tr>
<td>43645</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption</td>
</tr>
<tr>
<td>43770</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)</td>
</tr>
<tr>
<td>43771</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only</td>
</tr>
<tr>
<td>43772</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device component only</td>
</tr>
<tr>
<td>43773</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only</td>
</tr>
<tr>
<td>43774</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device and subcutaneous port components</td>
</tr>
<tr>
<td>43775</td>
<td>Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy)</td>
</tr>
<tr>
<td>43842</td>
<td>Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty</td>
</tr>
<tr>
<td>43843</td>
<td>Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty</td>
</tr>
<tr>
<td>43845</td>
<td>Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)</td>
</tr>
<tr>
<td>43846</td>
<td>Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy</td>
</tr>
<tr>
<td>43847</td>
<td>Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption</td>
</tr>
</tbody>
</table>
### CPT®* Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>43848</td>
<td>Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)</td>
</tr>
<tr>
<td>43860</td>
<td>Revision of gastrojejunostomy (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; without vagotomy</td>
</tr>
<tr>
<td>43865</td>
<td>Revision of gastrojejunostomy (gastrojejunostomy) with reconstruction, with or without partial gastrectomy or intestine resection; with vagotomy</td>
</tr>
<tr>
<td>43886</td>
<td>Gastric restrictive procedure, open; revision of subcutaneous port component only</td>
</tr>
<tr>
<td>43887</td>
<td>Gastric restrictive procedure, open; removal of subcutaneous port component only</td>
</tr>
<tr>
<td>43888</td>
<td>Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only</td>
</tr>
</tbody>
</table>

*CPT Copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

### HCPCS Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2083</td>
<td>Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of saline</td>
</tr>
</tbody>
</table>

### ICD-10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E10-E13.9</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>E66-E66.9</td>
<td>Overweight and obesity</td>
</tr>
<tr>
<td>E74-E74.9</td>
<td>Other disorders of carbohydrate metabolism</td>
</tr>
<tr>
<td>E78-E78.9</td>
<td>Disorders of lipoprotein metabolism</td>
</tr>
<tr>
<td>G47-G47.9</td>
<td>Sleep disorder</td>
</tr>
<tr>
<td>G93.2</td>
<td>Benign intracranial hypertension</td>
</tr>
<tr>
<td>I10-I15</td>
<td>Hypertensive diseases</td>
</tr>
<tr>
<td>I20-I20.9</td>
<td>Angina pectoris</td>
</tr>
<tr>
<td>I25-I25.9</td>
<td>Chronic ischemic heart disease</td>
</tr>
<tr>
<td>I27-I27.9</td>
<td>Other pulmonary heart disease</td>
</tr>
<tr>
<td>I42-I42.9</td>
<td>Cardiomyopathy</td>
</tr>
<tr>
<td>I50-I50.9</td>
<td>Heart failure</td>
</tr>
<tr>
<td>I67-I67.9</td>
<td>Other cerebrovascular diseases</td>
</tr>
<tr>
<td>I83-I83.93</td>
<td>Varicose veins of lower extremities</td>
</tr>
<tr>
<td>K21-K21.9</td>
<td>Gastro-esophageal reflux disease</td>
</tr>
<tr>
<td>K31.1</td>
<td>Adult hypertrophic pyloric stenosis</td>
</tr>
<tr>
<td>K31.6</td>
<td>Fistula of stomach and duodenum</td>
</tr>
<tr>
<td>ICD-10 Codes</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>K56.5</td>
<td>Intestinal adhesions [bands] with obstruction (postprocedural) (postinfection)</td>
</tr>
<tr>
<td>K68-K68.9</td>
<td>Disorders of retroperitoneum</td>
</tr>
<tr>
<td>K91-K91.89</td>
<td>Intraoperative and postprocedural complications and disorders, not elsewhere classified</td>
</tr>
<tr>
<td>M16-M16.9</td>
<td>Osteoarthritis of hip</td>
</tr>
<tr>
<td>M24-M24.9</td>
<td>Other specific joint derangements</td>
</tr>
<tr>
<td>M25.879-M25.8-</td>
<td>Other specified joint disorders</td>
</tr>
<tr>
<td>M50-M50.93</td>
<td>Cervical disc disorders</td>
</tr>
<tr>
<td>M51-MM51.9</td>
<td>Thoracic, thoracolumbar, and lumbosacral intervertebral disc disorders</td>
</tr>
<tr>
<td>M53-M53.9</td>
<td>Other and unspecified dorsopathies, not elsewhere classified</td>
</tr>
<tr>
<td>M54-M54.9</td>
<td>Dorsalgia</td>
</tr>
<tr>
<td>R06-R06.9</td>
<td>Dyspnea</td>
</tr>
<tr>
<td>R09-R09.89</td>
<td>Other symptoms and signs involving the circulatory and respiratory systems</td>
</tr>
<tr>
<td>R26-R26.9</td>
<td>Abnormalities of gait and mobility</td>
</tr>
<tr>
<td>T85.59-T85.598</td>
<td>Other mechanical complication of gastrointestinal prosthetic devices, implants and grafts</td>
</tr>
<tr>
<td>T81-T81.9</td>
<td>Complications of procedures, not elsewhere classified</td>
</tr>
</tbody>
</table>

### Revision Log

<table>
<thead>
<tr>
<th>Revision Details</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarified process for processing requests when members are 59+ years</td>
<td>10/2/2015</td>
</tr>
<tr>
<td>Changed criteria for low cardiac risk patients to include clearance by a PCP in addition to cardiologist. Pulmonary evaluation criteria changed to include screening for OSA, limiting PFT to at-risk patients. Added in criteria for reversal.</td>
<td>5/31/2016</td>
</tr>
<tr>
<td>Clarified requirement for documentation of at least 1 year free of drugs and alcohol if history of abuse; added requirement for negative UDS within 3 months of request if history of abuse. Added Investigational and Not Medically Necessary procedures.</td>
<td>5/17/2017</td>
</tr>
<tr>
<td>Added that psychological evaluation must be done in-person. Updated formatting.</td>
<td>8/22/2017</td>
</tr>
<tr>
<td>Modified section B.2 to include if waiting for program would be detrimental to the member’s health. Removed requirement for specific cardiac testing (stress</td>
<td>3/19/2018</td>
</tr>
</tbody>
</table>
test, echocardiogram) for high cardiac risk candidates and revised to state they require consultation/evaluation and cardiac clearance from a cardiologist.

References


11. Lim RB. Bariatric surgical operations for the management of severe obesity: Descriptions. In: UpToDate, Jones D (Ed), UpToDate, Waltham, MA. Accessed 08/15/2016.


Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective
date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and
regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical
policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not
intended to dictate to providers how to practice medicine. Providers are expected to exercise professional
medical judgment in providing the most appropriate care, and are solely responsible for the medical
advice and treatment of members. This clinical policy is not intended to recommend treatment for
members. Members should consult with their treating physician in connection with diagnosis and
treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent
judgment and over whom the Health Plan has no control or right of control. Providers are not agents or
employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this
clinical policy or any information contained herein are strictly prohibited. Providers, members and their
representatives are bound to the terms and conditions expressed herein through the terms of their
contracts. Where no such contract exists, providers, members and their representatives agree to be bound
by such terms and conditions by providing services to members and/or submitting claims for payment for
such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage
provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the
state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members**, to ensure consistency with the Medicare National Coverage
Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs
should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene
Corporation and are protected by United States copyright law and international copyright law. No part of
this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system,
transmitted in any form or by any means, or otherwise published without the prior written permission of
Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained
herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene
Corporation.